We manufacture crystal forms whose patient or commercial benefit is already established — but that cannot be produced at industrial scale on Earth. For your portfolio, that means two things.
The scenario. A molecule whose route to market is blocked by its crystal form, in one of two ways: the higher-performing form is metastable on Earth and converts before it reaches patients — or the right form is producible, but its crystal quality varies batch to batch.
What we change. Crystals grown in orbit have fewer defects — and fewer defects means fewer nucleation sites, so a metastable form can hold long enough to become a real product. Where the problem is consistency, diffusion-driven growth delivers the uniformity terrestrial processes can't: improved dissolution and bioavailability, a lower dose, reduced inter-batch variability, a stronger manufacturing position.
The scenario. A marketed drug approaching patent expiry, exposed to automatic generic substitution and steep revenue erosion.
What we change. A differentiated, patentable crystal form that generics cannot copy — giving the prescriber a clinical reason to prefer the brand, and the owner a way to hold market share past the cliff. The value case rests on real clinical differentiation: better, more uniform bioavailability from a superior solid form.
The orbital step does not have to fly for every batch. Published orbital experiments show seed crystals grown in microgravity propagating their form and quality through consecutive terrestrial generations. Where seeding holds, a single orbital batch templates commercial-scale production on the ground — making the cost of the orbital step amortisable across your terrestrial manufacturing.
For you, a standard API supply relationship. All the orbital complexity — spacecraft, launch, recovery — is ours.
Hand over a molecule, receive better material, delivered at your facility under agreed quality and documentation standards. No space expertise required on your side.
The programme is milestone-based: payments are due only against delivered, verifiable milestones. ZGW carries the technical and execution risk, with exit gates at every stage.
We work with a single pharmaceutical partner at a time: the definitive agreement grants exclusivity on ZGW's orbital pathway for its duration.
Write to info [at] zerogravityworks [dot] com